Autologous Stem Cell Rescue for Primary Amyloidosis
AmyloidosisBlood and Marrow Transplant (BMT)To evaluate the role of high dose therapy and autologous hematopoietic cell transplant for amyloidosis.
Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis
Primary Systemic Amyloidosis (AL)AL amyloidosis is caused by a clonal plasma cell dyscrasia and characterized by progressive deposition of amyloid fibrils derived from monoclonal Ig light chains, leading to multisystem organ failure and death. The prognosis for AL amyloidosis with conventional treatment remains poor, Autologous stem cell transplantation (ASCT) for AL amyloidosis produces high hematologic and organ responses. However, treatment-related mortality remains high and reported series are subject to selection bias.
Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis
AmyloidosisPatients with primary systemic amyloidosis will be treated with CC-5013 (lenalidomide; Revlimid) as a single agent for 3 months. If their disease worsens or does not improve during that time frame dexamethasone will be added to the treatment program.
An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients...
Light Chain (AL) AmyloidosisThis is a Phase 1 open-label, dose escalation trial designed to identify the recommended phase 2 dose of STI-6129 by assessing the safety, preliminary efficacy, and immunogenicity in subjects with relapsed or refractory systemic AL Amyloidosis
Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory...
AmyloidosisImmunoglobulin Light Chain DepositionThis phase II trial studies how well ibrutinib with or without bortezomib and dexamethasone works in treating patients with immunoglobulin light chain amyloidosis that has come back after a period of improvement or that does not respond to treatment. Ibrutinib and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib with or without bortezomib and dexamethasone may work better in treating patients with relapsed or refractory immunoglobulin light chain amyloidosis.
Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
AmyloidAmyloidosis1 moreThe purpose of this study is to test the safety and efficacy of Selinexor and Dexamethasone and see what effects it has on AL amyloidosis.
High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease...
Primary Amyloidosis of Light Chain TypeThe aim of the study is to assess survival of patients with advanced cardiac AL amyloidosis treated with high cut-off hemodialysis (HCO-HD) combined with chemotherapy.
Mixed Chimeric Transplantation for Primary Amyloidosis
AmyloidosisTo evaluate the role of nonmyeloablative allogeneic transplantation in Amyloidosis.
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment...
Accelerated Phase Chronic Myelogenous LeukemiaAcute Undifferentiated Leukemia88 moreThis clinical trial studies massage therapy given by caregiver in treating quality of life of young patients undergoing treatment for cancer. Massage therapy given by a caregiver may improve the quality of life of young patients undergoing treatment for cancer
Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis
Immunoglobulin Light-Chain AmyloidosisResearch Objective:At present, there is no standard therapeutic regimen for monoclonal immunoglobulin light chain (AL) amyloidosis in the world. To compare the efficacy and safety of the regimens between bortezomib-thalidomide-dexamethasone (BTD) and bortezomib-cyclophosphamide-dexamethasone (BCD) in the treatment of AL amyloidosis, so as to provide more clinical evidence for the standard treatment for the disease. Research Design:This study was designed as a prospective, randomized and controlled clinical study. Patients who meet the inclusion criteria of this study will be randomized to the BTD scheme group or BCD scheme group.